196 related articles for article (PubMed ID: 37424868)
1. Tocilizumab improves clinical outcome in patients with active corticosteroid-resistant moderate-to-severe Graves' orbitopathy: an observational study.
Boutzios G; Chatzi S; Goules AV; Mina A; Charonis GC; Vlachoyiannopoulos PG; Tzioufas AG
Front Endocrinol (Lausanne); 2023; 14():1186105. PubMed ID: 37424868
[TBL] [Abstract][Full Text] [Related]
2. Treatment of corticosteroid-resistant Graves' orbitopathy with tocilizumab: a single-centre prospective study.
Dorado Cortez O; Grivet D; Perrillat N; Gain P; Thuret G
Orbit; 2023 Aug; 42(4):411-417. PubMed ID: 36065465
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab.
Moi L; Hamedani M; Ribi C
Clin Endocrinol (Oxf); 2022 Sep; 97(3):363-370. PubMed ID: 34908176
[TBL] [Abstract][Full Text] [Related]
4. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.
Sánchez-Bilbao L; Martínez-López D; Revenga M; López-Vázquez Á; Valls-Pascual E; Atienza-Mateo B; Valls-Espinosa B; Maiz-Alonso O; Blanco A; Torre-Salaberri I; Rodríguez-Méndez V; García-Aparicio Á; Veroz-González R; Jovaní V; Peiteado D; Sánchez-Orgaz M; Tomero E; Toyos-Sáenz de Miera FJ; Pinillos V; Aurrecoechea E; Mora Á; Conesa A; Fernández-Prada M; Troyano JA; Calvo-Río V; Demetrio-Pablo R; González-Mazón Í; Hernández JL; Castañeda S; González-Gay MÁ; Blanco R
J Clin Med; 2020 Aug; 9(9):. PubMed ID: 32878150
[TBL] [Abstract][Full Text] [Related]
6. Steroid-Resistant Graves' Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience.
Pérez-Moreiras JV; Varela-Agra M; Prada-Sánchez MC; Prada-Ramallal G
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670151
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab in glucocorticoid-resistant graves orbitopathy. A case series report of a mexican population.
Ceballos-Macías José J; Rivera-Moscoso R; Flores-Real Jorge A; Vargas-Sánchez J; Ortega-Gutiérrez G; Madriz-Prado R; Velasco-Ramos PC; Muñoz-Monroy Omar E; Meneses-Pérez Anna C; Fernández-Morales Irma N; Hernández-Moreno A
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):78-82. PubMed ID: 32340849
[TBL] [Abstract][Full Text] [Related]
8. Natural history of graves' orbitopathy after treatment.
Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study.
Lee C; Park JW; Kim YD; Woo KI
Int Ophthalmol; 2024 Apr; 44(1):179. PubMed ID: 38622479
[TBL] [Abstract][Full Text] [Related]
10. Treatment of active corticosteroid-resistant graves' orbitopathy.
Pérez-Moreiras JV; Alvarez-López A; Gómez EC
Ophthalmic Plast Reconstr Surg; 2014; 30(2):162-7. PubMed ID: 24503568
[TBL] [Abstract][Full Text] [Related]
11. Enduring remission of active and sight-threatening Graves' orbitopathy with rituximab: report of two cases.
Adamidou F; Anagnostis P; Boboridis K; Manani C; Georgiou T; Veneti S; Kita M
Endocr J; 2018 Sep; 65(9):963-967. PubMed ID: 29937466
[TBL] [Abstract][Full Text] [Related]
12. Success Treatment of Severe and Active Graves' Orbitopathy with Tocilizumab After Thyroidectomy and Maximum Dose of Intravenous Methylprednisolone.
Pramono LA
Acta Med Indones; 2023 Oct; 55(4):475-477. PubMed ID: 38213047
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids in Moderate-To-Severe Graves' Ophthalmopathy: Oral or Intravenous Therapy?
Penta L; Muzi G; Cofini M; Leonardi A; Lanciotti L; Esposito S
Int J Environ Res Public Health; 2019 Jan; 16(1):. PubMed ID: 30626069
[TBL] [Abstract][Full Text] [Related]
14. Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy-Preliminary Results From a Prospective Single-Center Study.
Sarnat-Kucharczyk M; Świerkot M; Handzlik G; Kulawik G; Jagoda K; Grochoła-Małecka I; Fryżewska J; Mrukwa-Kominek E; Chudek J
Front Endocrinol (Lausanne); 2022; 13():871009. PubMed ID: 35615718
[TBL] [Abstract][Full Text] [Related]
15. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
16. Association between Clinical Activity Score and Serum Interleukin-6, Interleukin-8 and Interleukin-10 during Systemic Glucocorticoid Treatment for Active Moderate-to-Severe Graves' Orbitopathy.
Stoynova MA; Shinkov AD; Georgiev GK; Kovatcheva RD
Curr Eye Res; 2021 Oct; 46(10):1503-1508. PubMed ID: 33849364
[No Abstract] [Full Text] [Related]
17. The effects of Rituximab on Graves'orbitopathy: A retrospective study of 14 patients.
Eid L; Coste-Verdier V; Longueville E; Ribeiro E; Nicolescu-Catargi B; Korobelnik JF
Eur J Ophthalmol; 2020 Sep; 30(5):1008-1013. PubMed ID: 31025590
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves' Orbitopathy.
Bennedjaï A; Bouheraoua N; Gatfossé M; Dupasquier-Fediaevsky L; Errera MH; Tazartes M; Borderie V; Hennocq Q; Dellal A; Riviere S; Heron E; Fain O; Mekinian A
Ocul Immunol Inflamm; 2022 Feb; 30(2):500-505. PubMed ID: 32965148
[TBL] [Abstract][Full Text] [Related]
19. Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves' Orbitopathy.
Campi I; Vannucchi G; Muller I; Lazzaroni E; Currò N; Dainese M; Montacchini B; Covelli D; Guastella C; Pignataro L; Fugazzola L; Arosio M; Salvi M
Front Endocrinol (Lausanne); 2021; 12():790246. PubMed ID: 35145479
[TBL] [Abstract][Full Text] [Related]
20. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.
Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA
Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
